Table 1. Characteristics of the glioblastomas with HCMV_UL73 positivity.
| Age (yr) | Sex | UL73 (Ct) | UL73 repeat (Ct) | UL144 | IHC | ISH | MSP | IDH1 | Ki67 (%) | PFS (mo) | OS (mo) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 67 | m | 35 | 36 | – | – | – | + | – | 25 | 10.3 | 16.7 |
| 40 | m | 39 | 40 | – | – | – | + | R132H | 85 | 2.9 | 13.3 |
| 9 | f | 38 | – | – | – | – | – | – | 70 | 5.6 | 14.6 |
| 72 | m | 38 | – | – | – | – | – | – | 50 | 5.5 | 13.1 |
| 56 | f | 38.3 | – | – | – | – | + | – | 40 | 8.4 | 15.5 |
| 75 | m | 38.4 | – | – | – | – | + | – | 90 | 16.4 | 20.3 |
| 37 | f | 39 | – | – | – | – | + | – | 20 | 7.6 | 23.9 |
| 54 | f | 39 | – | – | – | – | – | – | 70 | 4.7 | 10.7 |
| 57 | m | 40 | – | – | – | – | – | – | 60 | 3.1 | 8.9 |
Ct, PCR threshold cycle; MSP, MGMT methylation specific PCR; IDH1, isocitrate dehydrogenase 1 mutation; PFS, progression-free survival; OS, overall survival.